PRNewsWire
13 Jul 2026, 00:30 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Insilico Medicine is eligible to receive up to approximately 1.2 billion RMB in milestone payments plus royalties from the new collaboration with CMS. — This represents a significant potential cash inflow and revenue stream for Insilico Medicine, directly impacting its valuation.
+0.60Insilico Medicine and CMS have entered a new AI-powered drug discovery collaboration targeting a mass-market CNS disease indication. — Expanding into mass-market CNS indications increases the total addressable market and validates the commercial utility of Insilico's AI platform.
+0.40Insilico Medicine and CMS are deepening their strategic partnership just three months after their initial collaboration announcement. — The rapid expansion of the partnership suggests high operational synergy and confidence in the AI-driven R&D results.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company entered a new AI-powered drug discovery collaboration and is eligible for up to 1.2 billion RMB in milestone payments.
The company is deepening its AI R&D capabilities through a strategic collaboration to accelerate the delivery of clinical innovations.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
3h ago
